Cipla (BOM:500087) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500087 Cipla Ltd BOM:500087
96 GF Score
Price ₹1,371.45
GF Value ₹1,575.78
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Cipla Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cipla  (BOM:500087) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cipla Cyclically Adjusted PS Ratio Related Terms


Cipla Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Cipla's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Cyclically Adjusted PS Ratio Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.58 3.66 5.58 5.01 3.97

Cipla Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.05 4.92 4.87 3.90 4.56

BOM:500087 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cipla's Cyclically Adjusted PS Ratio falls into.


BOM:500087
96GF Score
Cipla Ltd BOM:500087
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cipla's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cipla's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=88.061/167.3573*167.3573
=88.061

Current CPI (Jun. 2026) = 167.3573.

Cipla Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 46.578 105.961 73.566
201612 45.247 105.196 71.984
201703 44.525 105.196 70.835
201706 43.716 107.109 68.306
201709 50.621 109.021 77.708
201712 48.567 109.404 74.294
201803 45.931 109.786 70.017
201806 48.795 111.317 73.360
201809 49.690 115.142 72.224
201812 49.742 115.142 72.299
201903 54.570 118.202 77.263
201906 49.502 120.880 68.535
201909 54.463 123.175 73.999
201912 54.216 126.235 71.877
202003 54.279 124.705 72.844
202006 53.847 127.000 70.958
202009 62.389 130.118 80.245
202012 63.974 130.889 81.798
202103 57.054 131.771 72.462
202106 68.157 134.084 85.070
202109 68.284 135.847 84.123
202112 67.828 138.161 82.162
202203 65.088 138.822 78.467
202206 66.563 142.347 78.258
202209 72.183 144.661 83.508
202212 71.984 145.763 82.648
202303 71.106 146.865 81.028
202306 78.372 150.280 87.278
202309 82.672 151.492 91.330
202312 81.742 152.924 89.457
202403 76.266 153.035 83.404
202406 82.819 155.789 88.969
202409 87.263 157.882 92.500
202412 87.505 158.323 92.498
202503 83.278 157.552 88.461
202506 86.109 159.755 90.207
202509 93.915 162.289 96.848
202512 87.515 163.281 89.700
202603 80.904 164.272 82.423
202606 88.061 167.357 88.061

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cipla (BOM:500087) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of ₹1,371.45 is trading 13% below its estimated GF Value™ of ₹1,575.78. GuruFocus considers Cipla to be Modestly Undervalued.

Key valuation signals for BOM:500087:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹1,575.78 vs. price of ₹1,371.45 (13% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the BOM:500087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipla Business Description

Other Exchanges CIPLA:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
96GF Score

Get the complete analysis for BOM:500087

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,371.45
Price
₹1,575.78
GF Value